nach oben

Erschienen in:

01.12.2007 | ORIGINAL PAPER

The treatment of hepatic encephalopathy

verfasst von: Marsha Y. Morgan, A. Blei, K. Grüngreiff, R. Jalan, G. Kircheis, G. Marchesini, O. Riggio, Karin Weissenborn

Erschienen in: Metabolic Brain Disease | Ausgabe 3-4/2007

Einloggen, um Zugang zu erhalten

Abstract

Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.

Als-Nielsen B, Gluud LL, Gluud C (2004a) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 328:1046–1051PubMedCrossRef

Als-Nielsen B, Gluud LL, Gluud C (2004b) Non-absorbable disaccharides for hepatic encephalopathy (Cochrane review). In: The Cochrane Library, Issue 2. Wiley, Chichester, UK

Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C (2004c) Branched-chain amino acids for hepatic encephalopathy (Cochrane review). In: The Cochrane Library, Issue 2. Wiley, Chichester, UK

Bass NM (2006) The current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 25(1):23–31

Bircher J, Müller J, Guggenheim P, Hammerli UP (1966) Treatment of chronic portal systemic encephalopathy with lactulose. Lancet i:890–892

Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G et al (1994) Lactulose–neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol 18:1063–1068PubMed

Blei AT (2004) Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol 40:327–330PubMedCrossRef

Canales JJ, Elayadi A, Errami M, Llansola M, Cauli O, Felipo V (2003) Chronic hyperammonemia alters motor and neurochemical responses to activation of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo. Neurobiol Dis 14:380–390PubMedCrossRef

Chandra RK, McBean LD (1994) Zinc and immunity. Nutrition 10:79–80PubMed

Conn HO, Lieberthal MM (1979) The hepatic coma syndromes and lactulose. Williams and Wilkins, Baltimore

Córdoba J, Mínguez B, Vergara M (2005) Treatment of hepatic encephalopathy. Lancet 365:1384–1385PubMedCrossRef

Dejong C, Deutz N, Soeters P (1993) Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J Clin Invest 92:2834–2840PubMedCrossRef

Dragon Y, Avraham Y, Ilan Y, Mechoulam R, Berry EM (2007) Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J (in press)

Erceg S, Monfort P, Hernandez-Viadel M, Rodrigo R, Montoliu C, Felipo V (2005) Oral administration of sidenafil restore learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology 41:299–306PubMedCrossRef

Fleig WE, Kircheis G, Spengler U, Zeuzem St, Görtelmeyer R, German–Austrian–Swiss Multicentre Study Group (1999) Placebo-controlled, double-blind evaluation of l-ornithine–l-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). J Hepatol 30(1):65CrossRef

Grüngreiff K, Presser HJ, Franke D, Lössner B, Abicht K, Kleine FD (1989) Correlations between zinc, amino acids and ammonia in liver cirrhosis. Z Gastroenterol 27:731–735PubMed

Grüngreiff K, Grüngreiff S, Reinhold D (2000) Zinc deficiency and hepatic encephalopathy. Results of a long-term zinc supplementation. Trace Elem Exp Med 13:21–31CrossRef

Henglein-Ottermann D (1976) Der Einfluβ von Ornithin-Aspartat auf die Experimentell erzeugte Hyperammoniämie. Klinisch-experimentelle Studie. Therapie der Gegenwart 115:1504–1518PubMed

Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T (1992) Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 16:1227–1235PubMed

Iwasa M, Matsumura K, Watanabe Y, Yamamoto M, Kaito M, Ikoma J et al (2003) Improvement of regional cerebral blood flow after treatment with branched-chain amino acid solutions in patients with cirrhosis. Eur J Gastroenterol Hepatol 15:733–737PubMedCrossRef

Jalan R, Kapoor D (2004) Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci 106:467–474PubMedCrossRef

Jalan R, Wright G, Davies NA, Hodges SJ (2007) L-ornithine-phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses (in press)

Kale RA, Gupta RK, Saraswat VA, Hasan KM, Trivedi R, Mishra AM et al (2006) Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 43:698–706PubMedCrossRef

Kalk H (1958) Die Klinik der akuten Leberinsuffizienz. Gastroenterologia 90:271–290PubMedCrossRef

Katayama K (2004) Ammonia metabolism and hepatic encephalopathy. Hepatol Res 30S:S71–S78

Kircheis G, Metz M, Frey S, Seiller E (1996) Correlation between pharmacokinetic aspects and clinical efficacy of l-ornithine–l-aspartate (OA): results of randomized, controlled clinical trials. J Hepatol 25(1):131

Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R et al (1997) Therapeutic efficacy of l-ornithine–l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled double-blind study. Hepatology 25:1351–1360PubMedCrossRef

Kunin CM, Chalmers TC, Leevy CM, Sebastyen SC, Lieber CS, Finland M (1960) Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease. N Engl J Med 262:380–385PubMedCrossRef

Lai D, Gorbach SL, Levitan R (1972) Intestinal microflora in patients with alcoholic cirrhosis: urea-splitting bacteria and neomycin resistance. Gastroenterology 62:275–279PubMed

Lanthier PL, Morgan MY, Ballantyne J (1984) Bromocriptine-associated ototoxicity. J Laryngol Otol 98:399–404PubMed

Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52:737–741PubMedCrossRef

Leonhardt H, Bungert HJ (1972) Therapie der schweren Hyperammoniämie. Med Klin 67:1052–1056PubMed

Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH et al (2004) Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: A randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatol Res 28:155–160PubMedCrossRef

Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM (2004) Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39:1441–1449PubMedCrossRef

Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M (1995) Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1–2 hepatic encephalopathy. J Hepatol 23:39–46CrossRef

Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C et al (2005) Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39:540–543CrossRef

Macbeth WA, Kass EH, McDermott WV Jr (1965) Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 191:399–403CrossRef

Malaguarnera M, Pistone G, Elivra R, Leotta C, Scarpello L, Liborio R (2005) Effect of l-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11:7197–7202PubMed

Marchesini G, Fabr A, Bianchi G, Brizi M, Zoloi M (1996) Zinc supplementation and amino-acid nitrogen-metabolism in patients with advanced cirrhosis. Hepatology 23:1084–1092PubMedCrossRef

Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C et al (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124:1792–1801PubMedCrossRef

Marshall AW, Jakobovits AW, Morgan MY (1982) Bromocriptine-associated hyponatraemia in cirrhosis. BMJ 285:1534–1535PubMed

Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V et al , Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group (2003) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38:51–58PubMedCrossRef

Matsuda I, Ohtani Y, Ohyanagi K, Yamamoto S (1987) Hyperammonemia related to carnitine metabolism with particular emphasis on ornithine transcarbamylase deficiency. Enzyme 38:251–255PubMed

Morgan MY, Hawley KE (1987) Lactitol versus lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7:1278–1284PubMedCrossRef

Morgan MY, Jakobovits AW, James IM, Sherlock S (1980) Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 78:663–670PubMed

Morgan MY, Alonso M, Stanger LC (1989) Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. J Hepatol 8:208–217PubMedCrossRef

Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A et al (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3:705–713PubMedCrossRef

Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R et al (2006) Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 38:3552–3555PubMedCrossRef

Olde Damink SW, Deutz N, Redhead D, Hayes P, Soeters P, Jalan R (2002) Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 36:1163–1171PubMedCrossRef

Olde Damink SW, Jalan R, Deutz NE, Redhead DN, Dejong CH, Hynd P et al (2003) The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 37:1277–1285PubMedCrossRef

Pedretti G, Calzetti C, Missale G, Fiaccadori F (1991) Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy in cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 23:175–178PubMed

Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M et al (2006) Efficacy of oral l-ornithine–l-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 5:281–288PubMed

Prasad AS, Rabbani P, Abasi A, Bowersox E (1978) Experimental zinc deficiency. Ann Intern Med 89:483–490PubMed

Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive function and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559PubMedCrossRef

Rabbani P, Prasad AS (1978) Plasma ammonia and liver ornithine carbamoyltransferase activity in zinc deficient rats. Am J Physiol 235:E203–E206PubMed

Raskind JY, El-Chaar GM (2000) The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34:630–638PubMedCrossRef

Reding P, Duchateau J, Bataille C (1984) Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 2:493–494PubMedCrossRef

Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO (2000) Effect of l-ornithine–l-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 47:571–574PubMedCrossRef

Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G et al (1991) Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 36:1204–1208PubMedCrossRef

Riggio O, Merli M, Capocaccia L, Caschera M, Zullo A, Pinto G et al (1992) Zinc supplementation reduces blood ammonia and increases liver transcarbamylase activity in experimental cirrhosis. Hepatology 16:785–789PubMedCrossRef

Romero-Gómez M, Ramos-Guerrero R, Grande L, de Terán LC, Corpus R, Camacho I et al (2004) Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 41:49–54PubMedCrossRef

Rössle M, Nasari I, Ochs A, Haag K (1997) Effekt einer Zinksubstitution auf die Ammoniakkonzentration und die hepatische Enzephalopathie bei Patienten mit Zirrhose und Shunt. Z Gastroenterol 35(96):A155

Schölmerich J (1987) Zinc and vitamin A in liver cirrhosis. In: Boyer JL, Bianchi L (eds) Liver cirrhosis. MTP, Lancaster, pp 421–432

Shawcross D, Jalan R (2005) Dispelling myths in the treatment of hepatic encephalopathy. Lancet 365:431–433PubMed

Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonaemia in cirrhosis. J Hepatol 40:247–254PubMedCrossRef

Shawcross DL, Wright G, Olde Damink SWM, Jalan R (2007) Role of ammonia and inflammation in minimal hepatic encephalopathy. Met Brain Dis 22:125–138CrossRef

Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E (1993) Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 19:424–430PubMedCrossRef

Stauch S, Kircheis G, Adler G, Beckh H, Ditschuneit H, Görtelmeyer R (1998) Oral l-ornithine–l-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 28:856–864PubMedCrossRef

Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA et al (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39:542–545PubMed

Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS (1992) Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16:138–144PubMedCrossRef

Tomiya T, Inoue Y, Yanase M, Arai M, Ikeda H, Tejima K et al (2002) Leucine stimulates the secretion of hepatocyte growth factor by hepatic stellate cells. Biochem Biophys Res Commun 297:1108–1111PubMedCrossRef

Uribe M, Rampollo O, Vargas F, Ravelli GP, Mundo F, Zapata L et al (1987) Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial. Hepatology 7:639–643PubMedCrossRef

Van der Rijt C, Schalm SW, Han S, Foelen K, De Jong G (1991) Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 100:1114–1118PubMed

van Leeuwen PA, van Berlo CL, Soeters PB (1988) New mode of action for lactulose. Lancet i:55–56CrossRef

Yamamoto M, Iwasa M, Matsumura K, Nakagawa Y, Fujita N, Kobayashi Y et al (2005) Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol 11:6792–6799PubMed

Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura S, Watanabe A et al (2001) Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 55:349–355PubMed

Titel: The treatment of hepatic encephalopathy
verfasst von: Marsha Y. Morgan
A. Blei
K. Grüngreiff
R. Jalan
G. Kircheis
G. Marchesini
O. Riggio
Karin Weissenborn
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 3-4/2007
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-007-9060-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2007

Neuronal cell death in hepatic encephalopathy

Tryptophan, adenosine, neurodegeneration and neuroprotection

Therapeutic studies in hepatic encephalopathy

Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA

Introduction